<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896127</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F2308</org_study_id>
    <nct_id>NCT02896127</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to
      placebo in patients with ankylosing spondylitis at Week 16 and long term efficacy and safety
      up to Week 52.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants who achieve an ASAS 20 response (Assessment of SpondyloArthritis International Society criteria)</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS20 response is defined as an improvement of ≥20% and ≥1 units on a scale of 10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who achieve an ASAS 40 reponse</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP over time</measure>
    <time_frame>Week 16</time_frame>
    <description>hsCRP is measured as a marker of inflammation from blood samples during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who achieve an ASAS 5/6</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BASDAI over time</measure>
    <time_frame>Week 16</time_frame>
    <description>The BASDAI consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 PCS over time</measure>
    <time_frame>Week 16</time_frame>
    <description>The SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ASQoL score over time</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASQoL is an instrument to assess health-related quality of life among adult patients with Ankylosing Spondylitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who achieve an ASAS partial remission</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Ankylosing Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly</description>
    <arm_group_label>Secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or non-pregnant, non-lactating female patients at least 18 years of age

        Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or
        radiologist's report) fulfilling the Modified New York criteria for AS:

          -  Active AS assessed by BASDAI ≥4 (0-10) at Baseline

          -  Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at Baseline

          -  Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline Patients should
             have had inadequate response or failure to respond to at least 2 NSAIDs at an
             approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each
             NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due
             to intolerance, toxicity or contraindications Patients who are regularly taking
             NSAIDs (including COX-1 or COX-2 inhibitors) as part of their AS therapy are required
             to be on a stable dose for at least 2 weeks before randomisation Patients who have
             been on a TNFα inhibitor (not more than one) must have experienced an inadequate
             response to previous or current treatment given at an approved dose for at least 3
             months prior to randomization or have been intolerant to at least one administration
             of an anti-TNFα agent

        Exclusion Criteria:

          -  Chest X-ray or MRI with evidence of ongoing infectious or malignant process

               -  Patients taking high potency opioid analgesics

               -  Previous exposure to secukinumab or any other biologic drug directly targeting
                  IL-17 or IL-17 receptor

               -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruntal</city>
        <zip>792 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 11</city>
        <zip>148 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wigan</city>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 9, 2016</lastchanged_date>
  <firstreceived_date>May 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing Spondyloarthritis</keyword>
  <keyword>Axial spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
